BioCentury | Jan 22, 2021
Regulation

CAR T Yescarta among new approvals by Japanese regulator

...proteinase inhibitor, known elsewhere as Prolastin-C from Grifols S.A. (Madrid:GRF; NASDAQ:GRFS); and Orladeyo berotralstat from BioCryst Pharmaceuticals Inc....
...Inc. Daiichi Pharmaceutical Co. Ltd. Ono Pharmaceutical Co. Ltd. Torii Pharmaceutical Co. Ltd. Takeda Pharmaceutical Co. Ltd. Helsinn Healthcare S.A. Grifols S.A. BioCryst Pharmaceuticals Inc....
BioCentury | Dec 22, 2020
Product Development

Dec. 21-23 COVID-19 roundup: U.S. secures 100M more doses of Pfizer-BioNTech vaccine; plus Merck, BioCryst, CureVac, NIH and Sputnik V

...with severe and critical COVID-19. Merck gained the program through its $425 million takeout of OncoImmune Inc. last month. BioCryst’s...
BioCentury | Dec 8, 2020
Deals

Dec. 7 Quick Takes: Sino pays $515M for Sinovac stake; plus BioCryst, Roivant, AbCellera, Syros, YZY, Maze

...capacity expansion for Sinovac's Phase III-stage inactivated virus vaccine, CoronaVac, plus other development and operational activities.BioCryst...
...berotralstat, and $200 million in credit from Athyrium Capital Management LP, $125 million of which BioCryst...
...with Alloy, named Broadwing Bio, is developing mAbs. Financial terms were not disclosed. BC Staff Maze Therapeutics Syros AbCellera Roivant Sciences Sinovac BioCryst...
BioCentury | Dec 5, 2020
Product Development

Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai

...Fintepla fenfluramine to treat Dravet.FDA approves oral, non-steroidal product for HAEFDA approved oral, once-daily Orladeyo berotralstat from BioCryst Pharmaceuticals Inc....
...FOLR) - Folate receptor 1 BC Staff maribavir (TAK-620, SHP620, 1263W94, Camvia) Masiviera, masitinib (AB1010, masican, masipro) STRO-002 bamlanivimab, LY-CoV555 (LY3819253) BioCryst Pharmaceuticals Inc. Zogenix Takeda Sutro...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

...IPH4102) Sofusa anti-PD1 ST-001 nanoFenretinide exoIL-12 TTI-621 (SIRPaFc, SIRPalphaFc) BNZ-1 Cobomarsen (MRG-106) hypericin (HBP-347, SGX301) Rhizen Pharmaceuticals S.A. Soligenix Inc. miRagen Therapeutics Inc. CerRx Inc. Innate Pharma S.A. BioCryst Pharmaceuticals Inc. Johnson...
BioCentury | Jun 26, 2020
Product Development

21st century pandemic, prehistoric clinical trials

...research networks. There are also several well-designed, industry-led trials, including from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), BioCryst Pharmaceuticals Inc....
BioCentury | Jun 26, 2020
Distillery Therapeutics

Biocryst’s galidesivir effective against Zika in macaques

...DISEASE CATEGORY: Infectious disease INDICATION: Zika virus Biocryst’s broad-spectrum viral RNA polymerase inhibitor galidesivir could prevent...
...day resulted in undetectable viral RNA levels in plasma and reduced levels in the CSF. BioCryst Pharmaceuticals Inc....
...MGH, MIT and Harvard, Cambridge, Mass. email: jwhitne2@bidmc.harvard.edu Claire Quang galidesivir (BCX4430) Beth Israel Deaconess Medical Center Harvard Medical School BioCryst Pharmaceuticals Inc. Viral...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

...of the anti-CD19 mAb and other pipeline programs. BioCryst raises $100M follow-on Rare disease company BioCryst Pharmaceuticals Inc....
...domain) member 4 S1P - Sphingosine 1-phosphate Robin Sawka, BioCentury Staff Illumina Ginkgo Bioworks Inc. Arena Pharmaceuticals Inc. Viela Bio Inc. BioCryst Pharmaceuticals Inc. Progenity...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...business officer. He was SVP of legal at Gilead Sciences Inc. (NASDAQ:GILD). Rare disease company BioCryst Pharmaceuticals Inc....
...Therapeutics Inc. Owlstone Medical Ltd. PCI Biotech Holding ASA CureVac AG Pfizer Inc. Oric Pharmaceuticals Inc. Kyowa Hakko Kirin Co. Ltd. StrideBio Inc. BioCryst Pharmaceuticals Inc....
BioCentury | Feb 18, 2020
Regulation

Regulatory Roundup: PharmaMar-Jazz, BioCryst products under FDA review; plus EU approvals of Vyndaqel, Beovu; and more

...compound (see "Deal Gives Jazz Late-Stage Asset" ). FDA is also reviewing berotralstat (BCX7353) from BioCryst Pharmaceuticals Inc....
...committee meeting for the second-generation kallikrein inhibitor ahead of its Dec. 3 PDUFA date (see "BioCryst...
...Vascular endothelial growth factor Paul Bonanos, Associate Editor Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) BCX7353 vadadustat (MT-6548, akb-6548) PharmaMar S.A. Jazz Pharmaceuticals plc BioCryst Pharmaceuticals Inc. Novartis...
Items per page:
1 - 10 of 462
BioCentury | Jan 22, 2021
Regulation

CAR T Yescarta among new approvals by Japanese regulator

...proteinase inhibitor, known elsewhere as Prolastin-C from Grifols S.A. (Madrid:GRF; NASDAQ:GRFS); and Orladeyo berotralstat from BioCryst Pharmaceuticals Inc....
...Inc. Daiichi Pharmaceutical Co. Ltd. Ono Pharmaceutical Co. Ltd. Torii Pharmaceutical Co. Ltd. Takeda Pharmaceutical Co. Ltd. Helsinn Healthcare S.A. Grifols S.A. BioCryst Pharmaceuticals Inc....
BioCentury | Dec 22, 2020
Product Development

Dec. 21-23 COVID-19 roundup: U.S. secures 100M more doses of Pfizer-BioNTech vaccine; plus Merck, BioCryst, CureVac, NIH and Sputnik V

...with severe and critical COVID-19. Merck gained the program through its $425 million takeout of OncoImmune Inc. last month. BioCryst’s...
BioCentury | Dec 8, 2020
Deals

Dec. 7 Quick Takes: Sino pays $515M for Sinovac stake; plus BioCryst, Roivant, AbCellera, Syros, YZY, Maze

...capacity expansion for Sinovac's Phase III-stage inactivated virus vaccine, CoronaVac, plus other development and operational activities.BioCryst...
...berotralstat, and $200 million in credit from Athyrium Capital Management LP, $125 million of which BioCryst...
...with Alloy, named Broadwing Bio, is developing mAbs. Financial terms were not disclosed. BC Staff Maze Therapeutics Syros AbCellera Roivant Sciences Sinovac BioCryst...
BioCentury | Dec 5, 2020
Product Development

Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai

...Fintepla fenfluramine to treat Dravet.FDA approves oral, non-steroidal product for HAEFDA approved oral, once-daily Orladeyo berotralstat from BioCryst Pharmaceuticals Inc....
...FOLR) - Folate receptor 1 BC Staff maribavir (TAK-620, SHP620, 1263W94, Camvia) Masiviera, masitinib (AB1010, masican, masipro) STRO-002 bamlanivimab, LY-CoV555 (LY3819253) BioCryst Pharmaceuticals Inc. Zogenix Takeda Sutro...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

...IPH4102) Sofusa anti-PD1 ST-001 nanoFenretinide exoIL-12 TTI-621 (SIRPaFc, SIRPalphaFc) BNZ-1 Cobomarsen (MRG-106) hypericin (HBP-347, SGX301) Rhizen Pharmaceuticals S.A. Soligenix Inc. miRagen Therapeutics Inc. CerRx Inc. Innate Pharma S.A. BioCryst Pharmaceuticals Inc. Johnson...
BioCentury | Jun 26, 2020
Product Development

21st century pandemic, prehistoric clinical trials

...research networks. There are also several well-designed, industry-led trials, including from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), BioCryst Pharmaceuticals Inc....
BioCentury | Jun 26, 2020
Distillery Therapeutics

Biocryst’s galidesivir effective against Zika in macaques

...DISEASE CATEGORY: Infectious disease INDICATION: Zika virus Biocryst’s broad-spectrum viral RNA polymerase inhibitor galidesivir could prevent...
...day resulted in undetectable viral RNA levels in plasma and reduced levels in the CSF. BioCryst Pharmaceuticals Inc....
...MGH, MIT and Harvard, Cambridge, Mass. email: jwhitne2@bidmc.harvard.edu Claire Quang galidesivir (BCX4430) Beth Israel Deaconess Medical Center Harvard Medical School BioCryst Pharmaceuticals Inc. Viral...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

...of the anti-CD19 mAb and other pipeline programs. BioCryst raises $100M follow-on Rare disease company BioCryst Pharmaceuticals Inc....
...domain) member 4 S1P - Sphingosine 1-phosphate Robin Sawka, BioCentury Staff Illumina Ginkgo Bioworks Inc. Arena Pharmaceuticals Inc. Viela Bio Inc. BioCryst Pharmaceuticals Inc. Progenity...
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...business officer. He was SVP of legal at Gilead Sciences Inc. (NASDAQ:GILD). Rare disease company BioCryst Pharmaceuticals Inc....
...Therapeutics Inc. Owlstone Medical Ltd. PCI Biotech Holding ASA CureVac AG Pfizer Inc. Oric Pharmaceuticals Inc. Kyowa Hakko Kirin Co. Ltd. StrideBio Inc. BioCryst Pharmaceuticals Inc....
BioCentury | Feb 18, 2020
Regulation

Regulatory Roundup: PharmaMar-Jazz, BioCryst products under FDA review; plus EU approvals of Vyndaqel, Beovu; and more

...compound (see "Deal Gives Jazz Late-Stage Asset" ). FDA is also reviewing berotralstat (BCX7353) from BioCryst Pharmaceuticals Inc....
...committee meeting for the second-generation kallikrein inhibitor ahead of its Dec. 3 PDUFA date (see "BioCryst...
...Vascular endothelial growth factor Paul Bonanos, Associate Editor Zepsyre, lurbinectedin (PM01183, PM1183, tryptamicidin) BCX7353 vadadustat (MT-6548, akb-6548) PharmaMar S.A. Jazz Pharmaceuticals plc BioCryst Pharmaceuticals Inc. Novartis...
Items per page:
1 - 10 of 462